SMC
CELG

Smith, Moore & Co’s Celgene Corp CELG Stock Holding History

Smith, Moore & Co’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,461
Closed -$227K – 333
2019
Q2 		$227K Buy
2,461
+40
+2% +$3.8K 0.05% 289
2019
Q1 		$228K Buy
+2,421
New +$212K 0.05% 282
2018
Q4 		– Sell
-3,073
Closed -$275K – 377
2018
Q3 		$275K Buy
+3,073
New +$272K 0.06% 266
2018
Q2 		– Sell
-2,363
Closed -$211K – 357
2018
Q1 		$211K Sell
2,363
-115
-5% -$11K 0.06% 290
2017
Q4 		$259K Sell
2,478
-1,889
-43% -$213K 0.07% 244
2017
Q3 		$637K Buy
4,367
+538
+14% +$73.3K 0.18% 116
2017
Q2 		$497K Sell
3,829
-65
-2% -$7.96K 0.17% 114
2017
Q1 		$485K Sell
3,894
-139
-3% -$16.6K 0.17% 111
2016
Q4 		$467K Buy
4,033
+200
+5% +$22.3K 0.18% 116
2016
Q3 		$401K Buy
3,833
+50
+1% +$5.41K 0.16% 124
2016
Q2 		$373K Buy
3,783
+366
+11% +$37.9K 0.15% 130
2016
Q1 		$342K Buy
+3,417
New +$352K 0.15% 133

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Smith, Moore & Co's CELG Position: Q3 2019 in Review

Smith, Moore & Co sold out of Celgene Corp (CELG) in Q3 2019, closing a stake of 2,461 shares — an estimated $227K sold.

Smith, Moore & Co first reported a position in CELG in Q1 2016 and held it in 12 quarters. The position peaked at $637K in Q3 2017. 1,245 funds tracked by Wall St. Rank hold CELG as of Q3 2019.

  • Smith, Moore & Co reported no remaining Celgene Corp position as of Q3 2019 after selling out during the quarter.
  • Smith, Moore & Co sold 2,461 Celgene Corp shares in Q3 2019, an estimated $227K.
  • Smith, Moore & Co first reported a position in Celgene Corp in Q1 2016 and held it in 12 quarters.
  • Smith, Moore & Co's Celgene Corp position peaked at $637K in Q3 2017.
  • 1,245 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2019.

Based on Smith, Moore & Co's 13F filing for Q3 2019, filed 7 Nov 2019.